Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

B.C. is a great place to work, play, raise a family, and be with loved ones. But like many other places in the world, we’ve ...

GLP-1 drugs like Ozempic and Mounjaro helped men with low testosterone raise their levels without hormone replacement in a ...

While GLP-1 medications like Semaglutide, Tirzepatide and Dulaglutide have shown significant promise for weight loss, bariatric surgery is still generally considered the more effective and durable ...

New weight management drugs could be used to create a global metabolic health revolution and improve longevity, if investment ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.